Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | 18 Hook Ave, Unit 101 TORONTO ON M6P 1T4 |
Tel: | 1-416-6691001 |
Website: | https://www.ventripoint.com |
IR: | See website |
Key People | ||
George Adams Executive Chairman of the Board | Alvira Macanovic President, Chief Executive Officer | Jimmy Jeon Chief Financial Officer |
Business Overview |
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company's Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart's structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system's proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI). |
Financial Overview |
For the nine months ended 30 September 2023, VentriPoint Diagnostics Ltd. revenues decreased 81% to C$8K. Net loss decreased 4% to C$3.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative decrease of 18% to C$2.1M (expense), Net Financing Income/Expense - Balancing increase from C$9K (expense) to C$31K (income). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $30.64M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.04M as of Sep 30, 2023 |
EBITDA (TTM): | -$4.73M as of Sep 30, 2023 |
Net annual income (TTM): | -$4.74M as of Sep 30, 2023 |
Free cash flow (TTM): | -$3.86M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 157,182,655 as of Feb 6, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |